健康元药业集团股份有限公司

Group 1 - The company has agreed to provide joint liability guarantees for its wholly-owned and controlled subsidiaries to apply for credit financing of up to RMB 20.201 billion or equivalent foreign currency from banks such as the National Development Bank [1][2][18] - The total amount of guarantees is approximately RMB 20.201 billion, with RMB 9.13 billion for subsidiaries with a debt-to-asset ratio exceeding 70% and RMB 19.288 billion for those below 70% [2] - The total guarantees account for 56.56% of the company's most recent audited total assets of RMB 35.718 billion, pending approval at the company's shareholders' meeting [2] Group 2 - The company has a total guarantee balance of RMB 2.983 billion as of March 31, 2025, with RMB 1.576 billion for subsidiaries with a debt-to-asset ratio exceeding 70% and RMB 1.407 billion for those below 70% [18] - The guarantee balance represents 20.52% of the company's most recent audited net assets attributable to shareholders of RMB 14.534 billion [18] - As of March 31, 2025, there are no overdue guarantees from the company or its controlled subsidiaries [19] Group 3 - The company has several wholly-owned and controlled subsidiaries, including Shenzhen Haibin Pharmaceutical Co., Ltd. and Shenzhen Taotai Pharmaceutical Co., Ltd., which are involved in various pharmaceutical and healthcare-related businesses [3][4][5] - The subsidiaries have different registered capitals and main business activities, such as the production and sale of pharmaceutical products, research and development, and import-export operations [3][4][5][6] - The company is actively involved in the pharmaceutical industry, focusing on the production of various drug forms, including oral solutions, tablets, and inhalation preparations [4][5][6] Group 4 - The company held its ninth board meeting on April 7, 2025, where it reviewed and approved the proposal for credit financing and guarantees for its subsidiaries [18] - The board authorized the company's legal representative or their authorized person to sign relevant documents regarding the credit financing and guarantees [18] - The proposal will be submitted for approval at the company's shareholders' meeting [18]